Cyclin E, a potential prognostic marker for breast cancer - PubMed (original) (raw)
. 1994 Jan 15;54(2):380-5.
Affiliations
- PMID: 7903908
Cyclin E, a potential prognostic marker for breast cancer
K Keyomarsi et al. Cancer Res. 1994.
Abstract
A fundamental cause of cancer is changed properties of genetic material, which may deregulate normal development of the tissue or provide selective growth advantage to the tumor cell. This deregulation of cell proliferation results from altered production of a handful of proteins that play key roles in progression through the eukaryotic cell cycle. Some of these proteins include tumor suppressor genes or oncogenes. However, no one general change or alteration of a critical gene has yet been found in all cancers. Using surgical material obtained from patients with various malignancies, we show that breast cancers and other solid tumors, as well as malignant lymphocytes from patients with lymphatic leukemia, show severe quantitative and qualitative alterations in cyclin E protein production independent of the S-phase fraction of the samples. Hence, these alterations represent a true difference between normal versus tumor tissue. In addition, in breast cancer, the alterations in cyclin E expression become progressively worse with increasing stage and grade of the tumor, suggesting its potential use as a new prognostic marker.
Similar articles
- Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
Peters MG, Vidal Mdel C, Giménez L, Mauro L, Armanasco E, Cresta C, Bal de Kier Joffé E, Puricelli L. Peters MG, et al. Oncol Rep. 2004 Nov;12(5):1143-50. Oncol Rep. 2004. PMID: 15492807 - Cell cycle dysregulation influences survival in high risk breast cancer patients.
Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C. Königsberg R, et al. Cancer Invest. 2008 Aug;26(7):734-40. doi: 10.1080/07357900801944864. Cancer Invest. 2008. PMID: 18665474 - E- and A-type cyclins as markers for cancer diagnosis and prognosis.
Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. Yasmeen A, et al. Expert Rev Mol Diagn. 2003 Sep;3(5):617-33. doi: 10.1586/14737159.3.5.617. Expert Rev Mol Diagn. 2003. PMID: 14510182 Review. - Overview of the biologic markers of breast cancer.
Porter-Jordan K, Lippman ME. Porter-Jordan K, et al. Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100. Hematol Oncol Clin North Am. 1994. PMID: 8150784 Review.
Cited by
- Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.
Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Mittendorf EA, et al. Cancer Res. 2012 Jul 1;72(13):3153-62. doi: 10.1158/0008-5472.CAN-11-4135. Epub 2012 May 7. Cancer Res. 2012. PMID: 22564522 Free PMC article. - Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms.
Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Porter DC, et al. Mol Cell Biol. 2001 Sep;21(18):6254-69. doi: 10.1128/MCB.21.18.6254-6269.2001. Mol Cell Biol. 2001. PMID: 11509668 Free PMC article. - A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy.
Mazumder S, DuPree EL, Almasan A. Mazumder S, et al. Curr Cancer Drug Targets. 2004 Feb;4(1):65-75. doi: 10.2174/1568009043481669. Curr Cancer Drug Targets. 2004. PMID: 14965268 Free PMC article. Review. - Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.
Pierson-Mullany LK, Lange CA. Pierson-Mullany LK, et al. Mol Cell Biol. 2004 Dec;24(24):10542-57. doi: 10.1128/MCB.24.24.10542-10557.2004. Mol Cell Biol. 2004. PMID: 15572662 Free PMC article. - COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.
Kulkarni S, Patil DB, Diaz LK, Wiley EL, Morrow M, Khan SA. Kulkarni S, et al. BMC Cancer. 2008 Jan 31;8:36. doi: 10.1186/1471-2407-8-36. BMC Cancer. 2008. PMID: 18237383 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases